Dupixent Approved to Treat Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
The FDA has approved the use of Dupixent (dupilumab; Sanofi and Regeneron) to treat moderate-to-severe atopic dermatitis in adolescent patients 12–17 years old.
Next post in Dermatitis
